

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b> 10/625,754	<b>Applicant(s)</b> LEVENTER ET AL.	
	<b>Examiner</b> Raymond J. Henley III	<b>Art Unit</b> 1614	

**All Participants:**
**Status of Application:** Pending

 (1) Raymond J. Henley III.

(3) \_\_\_\_\_.

 (2) Daniel A. Monaco.

(4) \_\_\_\_\_.

**Date of Interview:** 22 December 2005
**Time:** PM (E.D.T.)
**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No  
 If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

None

Claims discussed:

29-31

Prior art documents discussed:


References U-W listed on the 892 attached to the previous Office action

**Part II.**
**SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:**

- (i) agreed that a dosage range of from 25 mg -300mg is clearly supported at page 13, lines 25-26 of the present specification; and  
 (ii) authorization given for Examiner's Amendment.

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

  
 (Examiner/SPE Signature)

 \_\_\_\_\_  
 (Applicant/Applicant's Representative Signature — if appropriate)